The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Widau, Ryan
One or more keywords matched the following items that are connected to Widau, Ryan
Item TypeName
Concept Carcinoma, Hepatocellular
Academic Article Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH).
Academic Article Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Academic Article Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.
Academic Article Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
Academic Article Ramucirumab in patients with advanced hepatocellular carcinoma and elevated a-fetoprotein: Outcomes by treatment-emergent ascites.
Academic Article Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.
Academic Article Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).
Academic Article Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.
Academic Article Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
Academic Article Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.
Academic Article Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study.
Search Criteria
  • Carcinoma Hepatocellular